Desipramine, amantadine, or fluoxetine
in buprenorphine-maintained cocaine users
by
Oliveto A, Kosten TR, Schottenfeld R, Falcioni J, Ziedonis D.
Department of Psychiatry,
Yale School of Medicine, New Haven,
CT 06519, USA.
J Subst Abuse Treat 1995 Nov-Dec;12(6):423-8

ABSTRACT

The clinical efficacy of promising cocaine anti-craving medications was examined in combination with buprenorphine. Twenty-one opioid-dependent cocaine abusers were enrolled in a double-blind, 12-week trial in which they received on a daily basis buprenorphine (8 mg, s.l.) plus either desipramine (150 mg, p.o.), amantadine (300 mg, p.o.), or fluoxetine (60 mg, p.o.). Urine samples and self-reported drug use were obtained 1-3 times/week. The order of greatest patient retention across the 12 weeks was desipramine (83.3%) > amantadine (66.7%) > fluoxetine (20.0%). The desipramine and amantadine groups appeared to have greater increases in opioid- and cocaine-free urines than the fluoxetine group. These results suggest that desipramine and amantadine may facilitate greater opioid and cocaine abstinence than fluoxetine.

Users
History
Mu and kappa
Quails on coke
Crack and crime
Prenatal cocaine
Dopaminergic flies?
Dopaminergic agents
Coca leaves/cocaine
Cocaine immunization
The coke-craving brain
Cocaine and methylphenidate

01 02 03 04 05 06 07 08 09 10 11 12
13 14 15 16 17 18 19 20 21 22 23 24

Refs
HOME
HedWeb
cannabis-marijuana.com
Future Opioids
BLTC Research
Wirehead Hedonism
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best to Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide To
Healthy Mood Boosters For All The Family